Development of extracellular signal-regulated kinase inhibitors

Kimberly Burkhard1, Sarice Smith, Rahul Deshmukh

  • 1Department of Pharmaceutical Sciences, University of Maryland School of Pharmacy, Baltimore, MD 21201, USA.

Insights

This review explores methods for finding selective inhibitors of extracellular signal-regulated kinase (ERK) proteins. The focus is on ATP-independent mechanisms and substrate-selective compounds for potential anti-inflammatory drug development.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Pharmacology

Background:

  • Extracellular signal-regulated kinase (ERK) signaling regulates vital cellular functions like differentiation, proliferation, and inflammation.
  • Dysregulation of ERK signaling is linked to various diseases, highlighting the need for targeted therapeutic interventions.

Purpose of the Study:

  • To review strategies for identifying selective inhibitors of ERK proteins, focusing on ATP-independent mechanisms.
  • To emphasize methods for discovering substrate-selective small molecules relevant to inflammatory processes.

Main Methods:

  • Utilizing computer-aided drug design (CADD) for high-throughput screening of compounds targeting ERK docking domains.
  • Employing spectroscopic and structural biology techniques to assess ERK protein binding.
  • Conducting cell-based and organism-level assays to evaluate inhibitor efficacy and ERK-dependent functions.

Main Results:

  • CADD significantly enhances the efficiency of identifying biologically active compounds by pre-screening potential drug candidates.
  • Substrate-selective inhibitors can be developed by targeting unique ERK docking domains and disrupting specific substrate interactions.
  • The identified compounds demonstrate potential for modulating ERK-dependent inflammatory responses.

Conclusions:

  • Targeting ATP-independent mechanisms and substrate-selective interactions offers a promising avenue for developing novel ERK inhibitors.
  • Computer-aided drug design is a powerful tool for accelerating the discovery of selective ERK inhibitors.
  • Substrate-selective ERK inhibitors hold potential for therapeutic applications in inflammatory diseases.

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
Amplifying Signals via Enzymatic Cascade01:22

Amplifying Signals via Enzymatic Cascade

When a ligand binds to a cell-surface receptor, the receptor's intracellular domain changes shape, which may either activate its enzyme function or allow its binding to other molecules. The initial signal is amplified by most signal transduction pathways. This means that a single ligand molecule can activate multiple molecules of a downstream target. Proteins that relay a signal are most commonly phosphorylated at one or more sites, activating or inactivating the protein. Kinases catalyze the...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...